In:
FEBS Open Bio, Wiley, Vol. 8, No. 11 ( 2018-11), p. 1782-1793
Abstract:
To clarify the effects of a dipeptidyl peptidase‐4 ( DPP ‐4) inhibitor on whole‐body energy metabolism, we treated mice fed a high‐fat diet ( HFD ) with teneligliptin, a clinically available DPP ‐4 inhibitor. Teneligliptin significantly prevented HFD ‐induced obesity and obesity‐associated metabolic disorders. It also increased oxygen consumption rate and upregulated uncoupling protein 1 ( UCP 1) expression in both brown adipose tissue ( BAT ) and inguinal white adipose tissue ( iWAT ), suggesting that it enhances BAT function. Soluble DPP ‐4 inhibited β‐adrenoreceptor‐stimulated UCP 1 expression in primary adipocytes, and this inhibition was prevented in the presence of teneligliptin, or an extracellular signal‐related kinase inhibitor. These results indicate that soluble DPP ‐4 inhibits β‐adrenoreceptor‐stimulated UCP 1 induction and that chronic DPP ‐4 inhibitor treatment may prevent obesity through the activation of BAT function.
Type of Medium:
Online Resource
ISSN:
2211-5463
,
2211-5463
DOI:
10.1002/feb4.2018.8.issue-11
DOI:
10.1002/2211-5463.12498
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
2651702-4